The Company also offered 4086197 15 Non Convertible debentures with warrants

The company also offered 4086197 15 non convertible

This preview shows page 7 - 10 out of 31 pages.

- The Company also offered 40,86,197-15% Non-Convertible debentures with warrants attached to it on Rights basis in the proportion 25 NCDS with warrants 8,200 equity shares held (all were taken up). - Another 2,04,310-15% NCDS were also offered to the employees on an equitable basis (all were taken up). These would be redeemed in three instalments of Rs 66, Rs 67 and Rs 67 each at the end of 6th, 7th & 8th year respectively from the date of allotment debentures. - Each NCP carries a warrant entitling the holder to apply for one equity share of Rs 10 each at a premium of Rs 115 per share at one or more instalment as may be decided by the Board during the period between 36th months and 60th months from the date of allotment of NCDS at half yearly intervals. - The Company also offered 85,000-12% Full Convertible debentures with warrants of Rs 300 each for cash at par to Specified Entities of the Management Group. Part A of debenture would be converted into one
Image of page 7
equity share of Rs 10 each at a premium of Rs 115 per share on the date of allotment. Part B of Rs 175 of each debenture was to be converted into one equity share of Rs 10 at a premium of Rs 165 per share. On December 6th 1994, 26,40,694 equity shares of Rs 10 ech were allotted as per the terms of fully convertible debentures issued in December 1993, Part B of Rs 175 each. - Each debenture has a warrant attached to the entitling the holder to apply for 25 equity shares of Rs 10 each for cash at a premium of Rs 165 per share in one or more instalment as decided by the Board, during the period between expiry of 12th month and 60th months from the date of allotment of debentures. - On 5th December, 32,81,154 equity shares were issued to shareholders of erstwhile Crosslands Research Laboratories Ltd. on its amalgamation with the Company. - It went public in Oct.'93 to part-finance manufacturing facilities of bulk fluoroquinolones at Dewas, MP; and dosage forms at Paonta Sahib, Himachal Pradesh. For easier access to the European markets 1994 - The Expansion and Modernisation plant for manufacture of Ranitidine and Amoxycillin and a pilot plant for R&D at Toansa were commissioned. A new plant for manufacture of pharmaceutical dosage forms at Paonta Sahib was completed. - The company allotted one hundred thousand warrants without any face value to entities of the management group on 28th July. Each of such warrants entitles the holder to subscribe to fifty equity shares of
Image of page 8
Rs 10 each at a premium of Rs 390 per share within a period of 18 months from the date of allotment. - The Company offered 51,61,290 GDSs representing 51,61,290 equity share of Rs 10 each at a price of US .375 equivalent to 604.89 (at the rate of US .00 = 31.22) per GDS on 29th June. 1995 - A Global Alliance Agreement was signed with Eli Lilly and the Company, for marketing of pharmaceutical products in U.S.A. and other countries. For the purpose of Indian joint venture, a company under the name Ranbaxy Lilly company was incorporated.
Image of page 9
Image of page 10

You've reached the end of your free preview.

Want to read all 31 pages?

  • Fall '16
  • satish kv
  • Marketing, Generic drug, Ranbaxy Laboratories, Ranbaxy Laboratories Ltd

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes